Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Inovio surprised by Roche returning prostate cancer immunotherapy

This article was originally published in Scrip

Executive Summary

The CEO of Inovio Pharmaceuticals has said the decision of its partner Roche to return rights to its prostate cancer immunotherapy "was a surprise to us". Dr Joseph Kim, Inovio's president and CEO, told Scrip that the company had no idea the collaboration was about to be terminated when Inovio reported Q3 results on 10 November and said it was expecting to begin Phase I trials of the preclinical DNA vaccine with Roche in 2015. "We were told on Friday [14 November] and announced it first thing Monday [17 November]," he said. "I believe it was a surprise to the Roche development team as well," he added.


Related Content

Deal Watch: Roche Aborts But Regeneron, Amgen and Pfizer Sign Up


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts